Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Marit A C VermuntMerel van NulandLisa T van der HeijdenHilde RosingJos H BeijnenAndries M BergmanPublished in: Cancer chemotherapy and pharmacology (2022)
The PK profile of docetaxel was similar in mCPRC and mHSPC patients. Therefore, possible differences in toxicity between mCRPC and mHSPC patients cannot be explained by differences in docetaxel PK in our study population. These results suggest that treatment adaptations are not recommended in the new population of patients with mHSPC.